Drug Development

Articles

Lonza and Takeda have furthered their multiproduct partnership through collaborative efforts on a new cancer treatment-Alunbrig (brigatinib).

Lonza, Takeda Collaborate on New Cancer Treatment

The agreement gives Sanofi access to Biomunex’s proprietary bi- and multi-specific-antibody-generating platform.

Sanofi, Biomunex Sign Antibody Licensing Agreement

Sanofi’s Adacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis [Tdap] vaccine adsorbed) is approved for a repeat dose in people 10 through 64 years of age, 8 years or more after the first vaccination.

FDA Approves Expanded Use of Sanofi’s Tdap Vaccine

The new reagents are designed to support clinical-phase and commercialization stages of cell and gene therapy production and to enhance DNA transfection.

New Reagents Optimize Biologics Production

AbbVie and immunotherapy company Tizona Therapeutics will join forces to develop and commercialize CD39-targeted therapeutics to treat cancer.

AbbVie, Tizona to Develop Antibody Immunotherapy

The company has brought a second stream of high-throughput GMP peptide manufacturing online.

Almac Group Increases Peptide Manufacturing

Yasvanth Ashokraj works in Integrated Product Development at CIPLA.

Prashant Modak works in Integrated Product Development at CIPLA.

Kalpesh Sawant work in Integrated Product Development at CIPLA.

Praveen Date works in Integrated Product Development at CIPLA.

Swati Laud works in Integrated Product Development at CIPLA.

This article demonstrates how qualitative physical attributes testing can be used to characterize soft gel capsule rupture/disintegration during rectal administration.

Evaluating a New Quality Control Test for Soft Gelatin Rectal Capsules

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

New approaches seek to address formulation and delivery challenges for these complex molecules.

Considering Protein and Peptide Delivery

Teva Pharmaceuticals and Neos Therapeutics entered into a settlement and licensing agreement to resolve all ongoing litigation involving Neos' patents protecting its Cotempla (methylphenidate) extended-release orally disintegrating tablets.

Neos Therapeutics, Teva Settle on Patent Litigation for ADHD Drug

Agilent and other partners are funding development of Tapestri, a single-cell sequencing platform designed to help predict cancer relapse in individual patients and show the efficacy of gene-editing experiments.

Formulation and Drug Delivery